Normal view MARC view ISBD view

Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study

In Journlaof Association Physician of India
By: Deshmukh C.
Contributor(s): Parikh P | Baisane C | Amare-Kadam P | Bakshi A | Saikia T | .
Material type: materialTypeLabelArticleSeries: Vol 53 Issues 4.Publisher: 2005Description: 298.Subject(s): toxicity, Imatinib mesylate, dermatology, India | DDC classification: In: Journlaof Association Physician of IndiaSummary: A 29 year old male with Chronic Myeloid Leukemia (CML) in Chronic Phase was started on Imatinib Mesylate 400mg /day which was well tolerated. On regular follow up he had a complete hematological response in one month. After 4 months of treatment he presented with, erythema, dryness, hyperpigmentation, desquamation of his right leg and foot (Grade IV dermatitis) (Fig. 1). There was no history of any other drug intake or offending agent. Imatinib was withdrawn and patient was treated with local emollients and oral prednisolone 1 mg/Kg. His dermatitis completely resolved in 3 weeks (Fig. 2). Imatinib was restarted with no recurrence of dermatologic toxicity. He had a complete hematologic and cytogenetic response as on last follow up (>1 year).
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
(Browse shelf) Available AR6032

A 29 year old male with Chronic Myeloid Leukemia (CML) in Chronic Phase was started on Imatinib Mesylate 400mg
/day which was well tolerated. On regular follow up he had a complete hematological response in one month. After
4 months of treatment he presented with, erythema, dryness, hyperpigmentation, desquamation of his right leg and
foot (Grade IV dermatitis) (Fig. 1). There was no history of any other drug intake or offending agent. Imatinib was
withdrawn and patient was treated with local emollients and oral prednisolone 1 mg/Kg. His dermatitis completely
resolved in 3 weeks (Fig. 2). Imatinib was restarted with no recurrence of dermatologic toxicity. He had a complete
hematologic and cytogenetic response as on last follow up (>1 year).

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha